Why is the CSL share price falling on Wednesday?

The ASX market darling has had little share price movement of late.

| More on:
Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL has announced a new collaboration and licensing deal with a US company to access next-generation mRNA vaccine technology 
  • The CSL share price is down today in line with the broader healthcare sector 
  • Two CSL directors loaded up on more shares last month 

The CSL Limited (ASX: CSL) share price is slightly lower today, down 0.55% to $281.71 at the time of writing.

Meantime the S&P/ASX 200 Index (ASX: XJO) is up 0.34% to just above 7,000 points.

The market is a mixed bag today with some sectors up and some down. The S&P/ASX 200 Health Care Index (ASX: XHJ) is among those in the red, down 0.2% at the time of writing.

What did CSL announce today?

CSL has announced that it has entered into a new collaboration and licensing agreement.

The agreement is with Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT). It's costing CSL US$200 million upfront with further payments down the track if certain milestones are achieved. The companies have also agreed to profit sharing on future product sales.

Under the terms, CSL will have access to late-stage self-amplifying mRNA vaccine platform technology.

According to the release, Arcturus Therapeutics is developing next-generation mRNA vaccines.

CSL chief operating officer Paul McKenzie said:

This collaboration is an exciting opportunity to complement CSL's own next generation mRNA program with a partner who developed a platform to deliver late stage clinical supplies at scale. These combined capabilities will accelerate our journey in mRNA.

CSL is looking to develop and commercialise enhanced vaccines for the flu as well as 'multi-pathogen pandemic preparedness'.

CSL will have the exclusive licence to Arcturus' mRNA technology for the flu, COVID-19, and other respiratory viral diseases.

The license for multi-pathogen pandemic preparedness is non-exclusive but CSL has the right to make it exclusive at a later date.

The deal is subject to regulatory approvals.

What's next for the CSL share price?

As my colleague Monica reported, the CSL share price fell slightly last month.

The company held its annual general meeting on 12 October. CSL CEO and managing director Paul Perreault told shareholders the company was performing in line with its guidance for FY23.

On 17 October, CSL provided an update on its Vifor business. The company advised it expected more than 10% revenue growth in the medium term. CSL gave a new FY23 net profit after tax before amortisation (NPATA) guidance range of US$2.7 billion to US$2.8 billion, including Vifor sales.

Two company directors loaded up on more CSL shares during October. Non-executive director Alison Watkins AM invested $272,000 and non-executive director Dr Megan Clark AC invested $74,000.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Bronwyn Allen has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »